International Journal of Biological MacromoleculesBioinformaticsPeer-reviewed journal article
Implications Derived from S-Protein Variants of SARS-CoV-2 from Six Continents
Sk. Sarif HassaniD, Kenneth H. LundstromiD, Debmalya BarhiD, Raner José Santana SilvaiD, Bruno Silva AndradeiD, Vasco AzevedoiD, Pabitra Pal ChoudhuryiD, Giorgio PalùiD, Bruce D. UhaliD, Ramesh J. L. KandimallaiD, Murat Seyran, Amos LaliD, Samendra P. SherchaniD, Gajendra Kumar AzadiD, Alaa A. A. AljabaliiD, Adam BrufskyiD, Ángel Serrano‐ArocaiD, Parise AdadiiD, Tarek Mohamed Abd El‐AziziD, Elrashdy M Moustafa Mohamed RedwaniD, Kazuo TakayamaiD, Nima RezaeiiD, Murtaza M. TambuwalaiD, Vladimir Nikolaevich UverskyiD
Abstract
Spike (S) proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical determinants of the infectivity and antigenicity of the virus. Several mutations in the spike protein of SARS-CoV-2 have already been detected, and their effect in immune system evasion and enhanced transmission as a cause of increased morbidity and mortality are being investigated. From pathogenic and epidemiological perspectives, spike proteins are of prime interest to researchers. This study focused on the unique variants of S proteins from six continents Asia, Africa, Europe, Oceania, South America, and North America. In comparison to the other five continents, Africa (29.065%) had the highest percentage of unique S proteins. Notably, only North America had 87% (14046) of the total (16143) specific S proteins available in the NCBI database(across all continents). Based on the amino acid frequency distributions in the S protein variants from all the continents, the phylogenetic relationship implies that unique S proteins from North America were significantly different from those of the other five continents. Overtime, the unique variants originating from North America are most likely to spread to the other geographic locations through international travel or naturally by emerging mutations. Hence it is suggested that restriction of international travel should be considered, and massive vaccination as an utmost measure to combat the spread of COVID-19 pandemic. It is also further suggested that the efficacy of existing vaccines and future vaccine development must be reviewed with careful scrutiny, and if needed, further re-engineered based on requirements dictated by new emerging S protein variants.
- Citations
- 13
- FWCI
- 1.03
- Field percentile
- top 19%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Wide variabilities identified among spike proteins of SARS Cov2 globally-dominant variant identified
Abantika Pal, Aruna Pal·bioRxiv·Sep 26, 2020
- Analysis of SARS-CoV-2 genomes from across Africa reveals potentially clinically relevant mutations.
Modeline N. Longjohn, Olivia Sochi Egbule, … Benson Chuks Iweriebor·bioRxiv·Sep 8, 2020
- Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.
- Mutational insights among the structural proteins of SARS-CoV-2: frequencies and evolutionary trends in American countries
M. Abavisani, K. Rahimian, … Z. Meshkat·bioRxiv·Jun 22, 2022
- Natural variants in SARS-CoV-2 S protein pinpoint structural and functional hotspots; implications for prophylaxis and therapeutics strategies
Suman Pokhrel, Benjamin R. Kraemer, … Daria Mochly‐Rosen·Scientific ReportsPeer-reviewed·Jun 23, 2021
- High diversity in Delta variant across countries revealed via genome-wide analysis of SARS-CoV-2 beyond the Spike protein
Rohit Suratekar, Pritha Ghosh, … AJ Venkatakrishnan·Molecular Systems BiologyPeer-reviewed·Feb 1, 2022